Data / Drug companies / Be Pharmaceuticals Inc.
Be Pharmaceuticals Inc.: 29 products in the FDA NDC directory, labeler code 71839
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Be Pharmaceuticals Inc. (labeler code 71839) lists 29 products in the FDA National Drug Code Directory, covering 14 finished drugs by generic name. By type: 29 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on June 12, 2026.
The request: Watch Be Pharmaceuticals Inc. (FDA labeler code 71839): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 71839
- Products in commercial distribution
- 29
- Packages
- 35
- Finished drugs by generic name
- 14
- Prescription products
- 29
- Over the counter products
- 0
- Flagged as original packager
- 29 of 29 products that carry the flag
- Started marketing in the last 12 months
- 1
- Earliest marketing start
- May 13, 2019
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 29 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 29 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Enoxaparin sodium | 7 | 18 |
| Glycopyrrolate | 4 | 64 |
| Phenylephrine hydrochloride | 3 | 77 |
| Daptomycin | 2 | 25 |
| Heparin sodium | 2 | 23 |
| Neostigmine methylsulfate | 2 | 24 |
| Rocuronium bromide | 2 | 25 |
| Dalbavancin | 1 | 5 |
| Fosaprepitant | 1 | 10 |
| Succinylcholine chloride | 1 | 27 |
| Norepinephrine bitartrate | 1 | 25 |
| Carboprost tromethamine | 1 | 22 |
| Pantoprazole sodium | 1 | 54 |
| Sodium nitroprusside | 1 | 14 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection | 18 | 62.1% |
| Injection, solution | 6 | 20.7% |
| Injection, powder, lyophilized, for solution | 4 | 13.8% |
| Injection, powder, for solution | 1 | 3.4% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Dalbavancin | 71839-144 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | June 12, 2026 |
| Norepinephrine Bitartrate | 71839-143 | Injection | Generic drugs (ANDA) | December 30, 2023 |
| Rocuronium Bromide | 71839-142 | Injection, solution | Generic drugs (ANDA) | July 12, 2023 |
| Rocuronium Bromide | 71839-141 | Injection, solution | Generic drugs (ANDA) | July 12, 2023 |
| Phenylephrine Hydrochloride | 71839-129 | Injection | Generic drugs (ANDA) | July 10, 2023 |
| Phenylephrine Hydrochloride | 71839-128 | Injection | Generic drugs (ANDA) | July 10, 2023 |
| Phenylephrine Hydrochloride | 71839-127 | Injection | Generic drugs (ANDA) | July 10, 2023 |
| Enoxaparin sodium | 71839-116 | Injection | Generic drugs (ANDA) | June 16, 2023 |
| Enoxaparin sodium | 71839-115 | Injection | Generic drugs (ANDA) | June 16, 2023 |
| Enoxaparin sodium | 71839-113 | Injection | Generic drugs (ANDA) | June 16, 2023 |
| Enoxaparin sodium | 71839-112 | Injection | Generic drugs (ANDA) | June 16, 2023 |
| Enoxaparin sodium | 71839-111 | Injection | Generic drugs (ANDA) | June 16, 2023 |
| Enoxaparin sodium | 71839-110 | Injection | Generic drugs (ANDA) | June 16, 2023 |
| Enoxaparin sodium | 71839-109 | Injection | Generic drugs (ANDA) | June 16, 2023 |
| Carboprost tromethamine | 71839-137 | Injection, solution | Generic drugs (ANDA) | May 11, 2023 |
| Pantoprazole sodium | 71839-122 | Injection, powder, for solution | Generic drugs (ANDA) | May 25, 2022 |
| Glycopyrrolate | 71839-126 | Injection | Generic drugs (ANDA) | March 10, 2022 |
| Glycopyrrolate | 71839-125 | Injection | Generic drugs (ANDA) | March 10, 2022 |
| Glycopyrrolate | 71839-124 | Injection | Generic drugs (ANDA) | March 10, 2022 |
| Glycopyrrolate | 71839-123 | Injection | Generic drugs (ANDA) | March 10, 2022 |
| Succinylcholine Chloride | 71839-121 | Injection, solution | Generic drugs (ANDA) | February 7, 2022 |
| Sodium Nitroprusside | 71839-120 | Injection | Generic drugs (ANDA) | July 12, 2021 |
| Heparin Sodium | 71839-118 | Injection, solution | Generic drugs (ANDA) | December 29, 2020 |
| Heparin Sodium | 71839-117 | Injection, solution | Generic drugs (ANDA) | December 29, 2020 |
| Daptomycin | 71839-108 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | August 20, 2020 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.